Heidelberg Pharma AG and Huadong Medicine Co have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement.
Heidelberg Pharma AG and Huadong Medicine Co have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement.
Heidelberg Pharma has granted an Huadong exclusive license to develop and commercialise HDP-101 and HDP-103 in Asia (excluding Japan), plus exclusive opt-in rights for two more pipeline candidates, with a total deal value of up to USD930 million (EUR825 million).
Huadong will also participate in a rights issue and acquire a percentage of current Heidelberg Pharma shareholdings from existing shareholders including dievini, totalling EUR105 million, making it the second largest investor in the business, behind dievini.
